The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | Advice for treating Waldenström’s macroglobulinemia in the second line
Neil Berinstein, MD, Sunnybrook Odette Cancer Centre, Toronto, Canada, discusses the second-line treatment of patients with Waldenström’s macroglobulinemia. He mentions several factors that may impact treatment decisions, including which agents were used in the front line, comorbidities, and patient preferences. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: AstraZeneca; Advisory Board: AstraZeneca, Abbvie, BeiGene.
